Basilea signs exclusive distribution agreement for Zevtera(r) (ceftobiprole medocaril) in the Middle East and North Africa with Hikma Pharmaceuticals LLC
October 15, 2015 01:20 ET
|
Basilea Pharmaceutica Ltd.
Hikma to commercialize antibiotic Zevtera® in the Middle East and North Africa (MENA) region
Agreement expands the global availability of Zevtera®
BASEL, Switzerland, Oct. 15,...
Basilea announces that Health Canada approved ZEVTERA(r) for the treatment of bacterial lung infections
October 12, 2015 01:18 ET
|
Basilea Pharmaceutica Ltd.
BASEL, Switzerland, Oct. 12, 2015 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Health Canada has approved ZEVTERA® (ceftobiprole medocaril) for the treatment of...
Basilea's Chief Technology Officer Dr. Ingrid Heinze-Krauss to retire and Dr. Gunter Ditzinger named as successor
August 28, 2015 01:18 ET
|
Basilea Pharmaceutica Ltd.
BASEL, Switzerland, Aug. 28, 2015 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) reports today that Dr. Ingrid Heinze-Krauss will retire after 15 years with the company. Basilea named Dr....
Basilea reports 2015 half-year results - Major milestones achieved for CRESEMBA(R) and Zevtera(R)
August 14, 2015 01:19 ET
|
Basilea Pharmaceutica Ltd.
Antifungal CRESEMBA® (isavuconazole) received U.S. approval and is recommended for approval in the European Union
Antibiotic Zevtera®/Mabelio® (ceftobiprole medocaril) launched...
Basilea announces that CHMP recommends approval of isavuconazole (CRESEMBA(R)) as a treatment for invasive aspergillosis and mucormycosis in the European Union
July 24, 2015 07:48 ET
|
Basilea Pharmaceutica Ltd.
BASEL, Switzerland, July 24, 2015 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...
Basilea reports solid 2014 full-year results, preparing the ground for commercialization of Zevtera(R) in Europe
February 17, 2015 01:19 ET
|
Basilea Pharmaceutica Ltd.
Antifungal isavuconazole U.S. NDA and European MAA submissions under regulatory review - decisions expected in Q1 2015 in the U.S. and Q4 2015 in the EU
First commercial launch of...
Swissmedic approves Basilea's antibiotic Zevtera(r) (ceftobiprole medocaril) for the treatment of pneumonia
December 22, 2014 01:18 ET
|
Basilea Pharmaceutica Ltd.
BASEL, Switzerland, Dec. 22, 2014 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) reports that the Swiss regulatory authority Swissmedic has approved the antibiotic Zevtera®...
Basilea announces launch of antibiotic Zevtera(r) (ceftobiprole medocaril) in Germany
December 05, 2014 01:21 ET
|
Basilea Pharmaceutica Ltd.
First commercial launch
BASEL, Switzerland, Dec. 5, 2014 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) announces today that its broad-spectrum antibiotic, Zevtera®...
Basilea to launch Zevtera(r)/Mabelio(r) (ceftobiprole medocaril) in Europe through a commercial services provider
July 21, 2014 01:22 ET
|
Basilea Pharmaceutica Ltd.
BASEL, Switzerland, July 21, 2014 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) reports that it has entered into an agreement with Quintiles (NYSE: Q) for the commercialization of...